Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 23%
Buy 8%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health is well-positioned for long-term growth with its expanding subscriber base, international expansion efforts, successful partnerships, and investments in new initiatives. However, the company may face challenges such as regulatory changes and competition in the market, which may impact their adjusted EBITDA in the short term. Nonetheless, its strong financials and potential for $1B in revenue make it a promising investment opportunity for the future.

Bears say

Hims & Hers Health is a prominent direct-to-consumer telehealth company that offers a wide range of healthcare products and services through its digital platform. Despite strong revenue growth and partnerships with companies like Novo Nordisk and Eucalyptus, the company's financials have been impacted by international expansion, investments in new therapies and AI, and strategic shifts in its weight loss offerings. The company's DTC-focused model relies on maintaining strong marketing yields and customer retention, which could be challenged by potential regulatory changes that may limit their ability to offer personalized compounded medications. With a negative outlook, the analyst values the company's FY26 estimates at an EV/sales multiple of 3.4x, lower than the 20%+ tech comp group average of 5.2x indicating potential risk for investors.

HIMS has been analyzed by 13 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 8% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 13 analysts, HIMS has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.